Exopharm

CY 2019 ASX Announcements

09/04/2019 – Investor Presentation

27/02/2019 – Explainer: The critical bottleneck of exosome isolation and the power of Exopharm’s LEAP technology

21/02/2019 – Appendix 4D and Dec 18 HY Report

02/02/2019 – Positive outcomes from initial animal studies of Plexaris and Exomeres

31/01/2018 – December 2018 Quarterly Cash Flow Report

31/01/2019 – December 2018 Quarterly Activities Report

 

CY 2018 ASX Announcements

28/12/18 – Investor Deck

18/12/18 – Initial Director Interests x 3

18/12/18 – Closes Initial Public Offering Fully Subscribed and Lists on the ASX

14/12/18 – Capital Structure and Restricted Securities

14/12/18 – Securities Trading Policy

14/12/18 – Updated Pro-Forma and Commitments

14/12/18 – Financial Statements – Year Ended 30 June 2018

14/12/18 – Financial Statements – Year Ended 30 June 2017

14/12/18 – Financial Statements – Year Ended 30 June 2016

14/12/18 – Constitution

14/12/18 – Prospectus

14/12/18 – Appendix 1A and Information Form and Checklist

14/12/18 – Top 20 Holders

14/12/18 – Distribution Schedule

14/12/18 – ASX Notice – Admission to the Official List